Casdin Partners Master Fund, L.P.
Known title: 10% OwnerCIK: 0001534265
Casdin Partners Master Fund, L.P.'s purchase track record
How the stock did after each of Casdin Partners Master Fund, L.P.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
18
of 18 since May 16, 2023
Stock higher 6 months later
22%
3 months: 39%
Median 6-month return
-17.7%
3 months: -6.5%
Beat the S&P 500
22%
median -26.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/3/2025 | LAB | $325K | -26.4% | -20.8% | +10.3% |
| 11/25/2025 | LAB | $10.02M | -19.0% | -23.2% | +11.1% |
| 11/17/2025 | LAB | $1.87M | -7.4% | -18.2% | +10.9% |
| 11/7/2025 | LAB | $2.23M | +11.5% | -9.7% | +10.0% |
| 9/3/2025 | LAB | $765K | +11.6% | -17.8% | +6.5% |
| 8/22/2025 | LAB | $659K | +8.7% | -11.0% | +6.8% |
| 8/13/2025 | LAB | $443K | -9.9% | -9.2% | +7.3% |
| 2/28/2025 | LAB | $5.13M | -5.6% | +17.8% | +8.5% |
| 8/20/2024 | LAB | $3.98M | -18.8% | -24.7% | +9.5% |
| 8/12/2024 | LAB | $4.09M | +40.3% | -17.6% | +13.5% |
| 8/2/2024 | LAB | $4.52M | +20.6% | -6.1% | +13.0% |
| 5/23/2024 | LAB | $260K | -25.3% | -37.9% | +12.9% |
| 5/15/2024 | LAB | $5.00M | -38.7% | -27.3% | +12.8% |
| 3/4/2024 | LAB | $646K | -3.9% | -23.3% | +7.8% |
| 10/19/2023 | BLFS | $10.37M | +52.2% | +41.7% | +17.1% |
| 8/9/2023 | BLFS | $772K | -11.4% | +37.4% | +11.8% |
| 5/17/2023 | LAB | $2.63M | +46.2% | +12.8% | +8.3% |
| 5/16/2023 | BLFS | $3.27M | -39.4% | -40.9% | +9.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
MaxCyte Appoints New Chief Corporate Development Officer. MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.
Transaction History
| BLFS | ▼ Sell | Open Market | 650,000 | $15.4M | 5/21/2026 | View on chart |
| BLFS | ▼ Sell | Open Market | 250,000 | $5.9M | 5/20/2026 | View on chart |
| BLFS | ▼ Sell | Open Market | 300,000 | $6.8M | 5/19/2026 | View on chart |
| LAB | ▲ Buy | Open Market | 150,000 | $217K | 12/4/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 75,000 | $108K | 12/3/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 125,000 | $178K | 12/2/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 7,550,000 | $9.8M | 11/25/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 150,000 | $215K | 11/24/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 450,000 | $586K | 11/20/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 350,000 | $449K | 11/19/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 275,000 | $339K | 11/18/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 225,000 | $276K | 11/17/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 250,000 | $310K | 11/14/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 450,000 | $541K | 11/13/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 375,000 | $446K | 11/12/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 300,000 | $359K | 11/11/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 275,000 | $322K | 11/10/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 225,000 | $253K | 11/7/2025 | View on chart |
| BLFS | ▼ Sell | Open Market | 750,000 | $21.4M | 10/15/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 100,000 | $129K | 9/9/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 250,000 | $319K | 9/4/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 250,000 | $316K | 9/3/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 125,000 | $158K | 8/26/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 200,000 | $248K | 8/25/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 200,000 | $253K | 8/22/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 150,000 | $183K | 8/15/2025 | View on chart |
| BLFS | ▼ Sell | Open Market | 500,000 | $12.2M | 8/15/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 133,220 | $162K | 8/14/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 75,000 | $98K | 8/13/2025 | View on chart |
| BLFS | ▼ Sell | Open Market | 500,000 | $11.3M | 8/11/2025 | View on chart |
| BLFS | ▼ Sell | Open Market | 1,000,000 | $23.8M | 6/10/2025 | View on chart |
| BLFS | ▼ Sell | Other | 27,994 | — | 4/7/2025 | View on chart |
| LAB | ▼ Sell | Other | 545,000 | $580K | 2/28/2025 | View on chart |
| LAB | ▼ Sell | Other | 545,000 | $580K | 2/28/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 4,820,959 | $5.1M | 2/28/2025 | View on chart |
| LAB | ▲ Buy | Grant | 58,215 | $62K | 2/28/2025 | View on chart |
| LAB | ▲ Buy | Open Market | 250,000 | $547K | 8/27/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 150,000 | $322K | 8/26/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 292,100 | $621K | 8/23/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 307,900 | $603K | 8/22/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 500,000 | $952K | 8/21/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 500,000 | $937K | 8/20/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 250,000 | $463K | 8/19/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 1,200,000 | $1.9M | 8/14/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 550,000 | $891K | 8/13/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 500,000 | $821K | 8/12/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 525,408 | $848K | 8/9/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 569,562 | $933K | 8/8/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 500,000 | $786K | 8/7/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 200,000 | $317K | 8/5/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 1,000,000 | $1.6M | 8/2/2024 | View on chart |
| LAB | ▼ Sell | Other | 655,000 | $1.3M | 6/18/2024 | View on chart |
| LAB | ▼ Sell | Other | 545,000 | $1.1M | 6/18/2024 | View on chart |
| LAB | ▼ Sell | Other | 1,200,000 | $2.5M | 6/18/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 100,000 | $260K | 5/23/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 150,000 | $388K | 5/22/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 350,000 | $896K | 5/21/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 100,000 | $258K | 5/20/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 352,072 | $902K | 5/17/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 500,000 | $1.3M | 5/16/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 500,000 | $1.3M | 5/15/2024 | View on chart |
| BLFS | ▼ Sell | Other | 150,000 | $2.6M | 4/30/2024 | View on chart |
| BLFS | ▼ Sell | Other | 150,000 | $2.6M | 4/30/2024 | View on chart |
| LAB | ▲ Buy | Grant | 32,525,821 | $89.4M | 3/18/2024 | View on chart |
| LAB | ▲ Buy | Grant | 13,939,637 | $38.3M | 3/18/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 1,403 | $4K | 3/5/2024 | View on chart |
| LAB | ▲ Buy | Open Market | 250,000 | $643K | 3/4/2024 | View on chart |
| LAB | ▲ Buy | Grant | 11,246,525 | — | 1/5/2024 | View on chart |
| LAB | ▲ Buy | Grant | 2,744,219 | — | 1/5/2024 | View on chart |
| BLFS | ▲ Buy | Open Market | 927,165 | $10.4M | 10/19/2023 | View on chart |
| BLFS | ▲ Buy | Open Market | 58,465 | $772K | 8/9/2023 | View on chart |
| BLFS | ▲ Buy | Open Market | 24,973 | $546K | 5/22/2023 | View on chart |
| LAB | ▲ Buy | Open Market | 800,000 | $1.8M | 5/19/2023 | View on chart |
| BLFS | ▲ Buy | Open Market | 50,000 | $1.1M | 5/19/2023 | View on chart |
| LAB | ▲ Buy | Open Market | 150,000 | $324K | 5/18/2023 | View on chart |
| BLFS | ▲ Buy | Open Market | 30,000 | $653K | 5/18/2023 | View on chart |
| LAB | ▲ Buy | Open Market | 250,000 | $472K | 5/17/2023 | View on chart |
| BLFS | ▲ Buy | Open Market | 30,027 | $639K | 5/17/2023 | View on chart |
| BLFS | ▲ Buy | Open Market | 15,000 | $303K | 5/16/2023 | View on chart |
| MXCT | ▼ Sell | Open Market | 735,786 | $4.5M | 10/3/2022 | View on chart |
| MXCT | ▼ Sell | Open Market | 3,235,548 | $13.9M | 7/1/2022 | View on chart |
| BLFS | ▼ Sell | Other | 126,185 | — | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analyst Pieces Highlight BioLife Solutions' Customer Retention, Momentum
Two analyst pieces this week focused on BioLife Solutions. Diamond Hill pointed to the company's high switching costs, suggesting customers face barriers to moving to competitors, which can support steady revenue. ChartMill separately noted the stock shows strong growth momentum along with a potential breakout setup. The stock is trading near the lower end of its 52-week range, while analysts maintain an average price target around $31, well above current levels.
Analyst Pieces Highlight BioLife Solutions' Customer Retention, Momentum. Two analyst pieces this week focused on BioLife Solutions. Diamond Hill pointed to the company's high switching costs, suggesting customers face barriers to moving to competitors, which can support steady revenue. ChartMill separately noted the stock shows strong growth momentum along with a potential breakout setup. The stock is trading near the lower end of its 52-week range, while analysts maintain an average price target around $31, well above current levels.